• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改进新药的管理准入:分享欧洲经验。

Improving the managed entry of new medicines: sharing experiences across Europe.

机构信息

Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439-41. doi: 10.1586/erp.12.44.

DOI:10.1586/erp.12.44
PMID:22971029
Abstract

The 3-day course on the managed entry of new medicines was run by the Piperska group, which is a pan-European group striving to enhance the health of the public as a whole and the individual patient through exchanging ideas and research around the rational use of drugs. Participants included health authority and health insurance personnel, academics and those from commercial organizations. The principal aim of the conference was to bring together people to discuss ways to improve the managed entry of new drugs.

摘要

为期三天的新药管理准入课程由 Piperska 集团组织,该集团是一个泛欧组织,通过围绕药物合理使用的交流思想和研究,努力增进公众和个别患者的健康。参与者包括卫生当局和健康保险公司人员、学者和商业组织的人员。会议的主要目的是召集人员讨论如何改进新药的管理准入。

相似文献

1
Improving the managed entry of new medicines: sharing experiences across Europe.改进新药的管理准入:分享欧洲经验。
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439-41. doi: 10.1586/erp.12.44.
2
Pharmaceutical expenditure and therapeutic value of new medicines in Spain.西班牙新药的药品支出与治疗价值
Pharmacoeconomics. 2003;21(16):1211-2. doi: 10.2165/00019053-200321160-00005.
3
Pharmaceutical expenditure compared across countries.各国药品支出对比。
Can J Clin Pharmacol. 2005 Fall;12(3):e269-75. Epub 2005 Dec 1.
4
Drugs still influence health costs, but trend abating.药物仍在影响医疗成本,但这种趋势正在减弱。
Capitation Rates Data. 2003 Oct;8(10):114-20.
5
A decade of growth in public and private pharmaceutical expenditures: the case of Belgium 1990-1999.1990 - 1999年比利时公共和私人药品支出十年增长情况
Acta Clin Belg. 2003 Sep-Oct;58(5):279-89; discussion 277-8. doi: 10.1179/acb.2003.58.5.003.
6
The European value-pricing game.欧洲价值定价博弈。
Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):5-6. doi: 10.1586/erp.11.85.
7
Prescription drug spending: contribution to health care spending and cost containment strategies.处方药支出:对医疗保健支出的贡献及成本控制策略
J Health Care Finance. 2006 Spring;32(3):8-19.
8
Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe.改善新药的管理性引入:分享经验以协助欧洲各国当局。
Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755-8. doi: 10.1586/14737167.2015.1085803. Epub 2015 Sep 14.
9
Spending on medicines in Israel in an international context.以色列药品支出的国际背景。
Isr Med Assoc J. 2005 May;7(5):286-91.
10
The impact of managed entry agreements on pharmaceutical prices.管理准入协议对药品价格的影响。
Health Econ. 2020 Oct;29 Suppl 1:47-62. doi: 10.1002/hec.4112. Epub 2020 Jul 6.

引用本文的文献

1
The Expiry of Humira Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.修美乐市场独占期的到期及阿达木单抗生物类似药在欧洲的进入:定价与国家政策措施概述
Front Pharmacol. 2021 Jan 8;11:591134. doi: 10.3389/fphar.2020.591134. eCollection 2020.
2
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.了解新上市药品定价和报销国际协议的趋势及其对药品可及性的影响:计算文本分析。
Global Health. 2020 Oct 14;16(1):98. doi: 10.1186/s12992-020-00633-9.
3
Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province.
南非某省公立部门医院药物与治疗学委员会的处方集管理活动及实践意义
Front Pharmacol. 2020 Aug 18;11:1267. doi: 10.3389/fphar.2020.01267. eCollection 2020.
4
Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.欧洲合理用药当前障碍映射(CORUM):现状与潜在解决方案
Front Pharmacol. 2020 Mar 3;11:144. doi: 10.3389/fphar.2020.00144. eCollection 2020.
5
Confidentiality agreements: a challenge in market regulation.保密协议:市场监管的挑战。
Int J Equity Health. 2019 Jun 3;18(1):11. doi: 10.1186/s12939-019-0916-3.
6
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.获取新药的障碍:探寻成本上升与预算有限之间的平衡
Front Public Health. 2018 Dec 5;6:328. doi: 10.3389/fpubh.2018.00328. eCollection 2018.
7
Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.欧洲药品管理局有条件批准药品的可及性与可负担性;韩国与其他国家的比较及启示
Front Pharmacol. 2018 Sep 3;9:938. doi: 10.3389/fphar.2018.00938. eCollection 2018.
8
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.中东欧实施管理准入协议:发现与启示。
Pharmacoeconomics. 2017 Dec;35(12):1271-1285. doi: 10.1007/s40273-017-0559-4.
9
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.支付方对可能采用适应性路径所带来变化的看法。
Front Pharmacol. 2016 Sep 28;7:305. doi: 10.3389/fphar.2016.00305. eCollection 2016.
10
Design and delivery of a tailored intervention to implement recommendations for multimorbid patients receiving polypharmacy into primary care practices.设计并实施一项针对性干预措施,将针对接受多种药物治疗的多病患者的建议纳入基层医疗实践。
Biomed Res Int. 2015;2015:938069. doi: 10.1155/2015/938069. Epub 2015 Jan 5.